Laura Lorenzetti

Stay informed with Laura Lorenzetti’s coverage and analysis for Fortune.

Page 45 of 73

  • captionA large Greek flag flies outside the Greek ParliamentFeatures

    Greece’s ultimatum and hackers stole millions from banks — 5 things to know today

    By
  • This file photo shows a Chinese man giving the other man Hongbao (a red envelope) with lucky money for Chinese Lunar New Year in Shanghai, China.International

    Alibaba’s Chairman Jack Ma tells staff: No red envelopes this year

    By
  • Apple To Debut New IPads As Tablet Rivals Crowd Maturing MarketFeatures

    Apple’s CEO on cybersecurity and Google’s new toy — 5 things to know today

    By
  • Demand For Measles Vaccine Increases As Outbreak Started At Disneyland In California SpreadsFeatures

    California’s statewide measles vaccination rate masks an unpleasant reality

    By
  • Features

    Expedia buying Orbitz and a Ukraine ceasefire — 5 things to know today

    By
  • Expedia Website Ahead Of Earnings FiguresFinance

    Expedia to buy rival Orbitz in a deal worth about $1.38 billion

    By
  • Inside Rite Aid Ahead of Earnings ReportsRetail

    Rite Aid takes aim at CVS with a $2 billion purchase

    By
  • Features

    Tesla’s update and the Greek drama continues — 5 things to know today

    By
  • Features

    Qualcomm’s big China fine and SpaceX tries again — 5 things to know today

    By
  • Netflix Garners Two Top Show Nominations With 'Cards,' 'Orange'Tech

    Cuba: Get ready to binge watch Orange is the New Black

    By
  • Alibaba To Kick Off IPO In U.S.Features

    Finance officials meet and Alibaba buys into smartphones — 5 things to know today

    By
  • 161135392Features

    Biosimilars may one day save your life. But what are they?

    By
  • Inside A Career Fair Ahead Of Jobless Claims FiguresFinance

    The streak continues: Employers added 257,000 jobs in January

    By
  • Features

    Health insurer hacked and Greek drama — 5 things to know today

    By
  • Merck’s bet on Keytruda is paying off in lung cancer.Finance

    FDA rescinds ‘breakthrough’ status for Merck’s hepatitis C drug

    By